Document:

Form of Stock Option Agreement under the Stock Incentive Plan

 Exhibit 10.2 
 DURATA THERAPEUTICS, INC. 
 STOCK INCENTIVE PLAN 

FORM OF STOCK OPTION AGREEMENT 
 THIS STOCK OPTION AGREEMENT (this “Option Agreement”) dated                     
by and between Durata Therapeutics, Inc., a Delaware corporation (the “Corporation”), and                      (the
“Participant”) evidences the stock option (the “Option”) granted by the Corporation to the Participant as to the number of shares of the Corporation’s Common Stock, par value $0.01 per share, first set forth
below. 
  

					
	Number of Shares of Common Stock:1	 	Award Date:
		
	Exercise Price per
Share:1 	 	Expiration Date:1,2
		
	Vesting Commencement Date:	 	
			
	Type of Option (check one):	  	Nonqualified Stock Option	 	[        ]
			
		  	Incentive Stock Option	 	[        ]
	  
 Vesting1,2 The Option shall become vested as 25% of the total number of shares of Common Stock subject to the Option on the first
anniversary of the Vesting Commencement Date. The remaining 75% of the total number of shares of Common Stock subject to the Option shall vest in 36 substantially equal monthly installments, with the first installment vesting on the last day of the
month following the month in which the first anniversary of the Vesting Commencement Date occurs and an additional installment vesting on the last day of each of the 35 months thereafter.

 The Option is granted under the Durata Therapeutics, Inc. Stock Incentive Plan (the
“Plan”) and subject to the Terms and Conditions of Stock Option (the “Terms”) attached to this Option Agreement (incorporated herein by this reference) and to the Plan. The Option has been granted to the Participant
in addition to, and not in lieu of, any other form of compensation otherwise payable or to be paid to the Participant. Capitalized terms are defined in the Plan if not defined herein. The parties agree to the terms of the Option set forth herein.
The Participant acknowledges receipt of a copy of the Terms and the Plan, specifically acknowledges and agrees to Section 13 of the Terms, and agrees to maintain in confidence all information provided to him/her in connection with the Option.

  

							
	 “PARTICIPANT”

 
	 	 	 	 DURATA THERAPEUTICS, INC.,
 a Delaware corporation

	Signature	 		 		 	
	  
	 		 	By:	 	  

	 Print Name
  
	 		 	Its:	 	  

	 Address
  
	 		 		 	
	  
 City, State, Zip
Code
	 		 		 	

  

	1 	 Subject to adjustment under Section 7.3.1 of the Plan. 

	2 	 Subject to early termination under Section 5.6 or 7.3 of the Plan. 

  
 - 1 -

 CONSENT OF SPOUSE 

In consideration of the Corporation’s execution of this Option Agreement, the undersigned spouse of the Participant agrees to be
bound by all of the terms and provisions hereof and of the Plan. 
  

					
	  	 		 	  
	Signature of Spouse	 		 	Date

 TERMS AND CONDITIONS OF STOCK OPTION 

 

	1.	Vesting; Limits on Exercise. 

 The Option shall vest and, except as provided in this Section 1, become exercisable in percentage installments of the aggregate number of shares subject to the Option as set forth on the cover page
of this Option Agreement. The Option may be exercised only to the extent the Option is vested and exercisable. 
  

	 	•	 	 Effect of Change in Control on Vesting. If a Qualifying Change in Control (as such term is defined in Exhibit 3) occurs while the
Participant is an employee of the Company and the Participant is not offered continued employment with the Company (or the acquiring or resulting entity as a result of such Qualifying Change in Control) following the consummation of such Qualifying
Change in Control, the Option, to the extent then outstanding and not vested, shall become fully vested upon (or to the extent appropriate to give effect to such accelerated vesting, immediately prior to) such Qualifying Change in Control. If,
however, a Change in Control (as defined in Exhibit 3) occurs and the prior sentence does not apply, the Option, to the extent then outstanding and not vested, shall become vested as to an additional portion of the Option such that 50% of the
total number of shares then subject to the Option that have not yet become vested as of such Change in Control shall become vested upon (or to the extent appropriate to give effect to such accelerated vesting, immediately prior to) such Change in
Control. 

  

	 	•	 	 Exercisability. Notwithstanding anything contained in the Plan or this Option Agreement to the contrary, the Option may not be exercised at any
time prior to the first to occur of (i) a Termination Event (as such term is defined in that certain Stockholders and Subscription Agreement of Durata Therapeutics, Inc., dated as of December 11, 2009, as amended from time to time, by and
among the Corporation and the other parties thereto) or (ii) the Participant’s Severance Date (the first of such events to occur, the “Triggering Event”). Upon the occurrence of the Triggering Event, a portion of the
Option (whether or not vested) shall terminate upon (or to the extent appropriate to give effect to such forfeiture, immediately prior to) such event, such portion of the Option to be determined by multiplying the total number of shares subject to
the Option at such time by the Forfeiture Percentage (in the event that any portion of the Option is unvested on the Triggering Event, the portion of the Option that shall terminate shall be determined proportionately against the vested and unvested
portion of the Option and, as to any unvested portion, proportionately as to any remaining vesting installments). The “Forfeiture Percentage” shall mean the percentage derived by dividing (a) the total amount obtained by
subtracting the amount, as of the Triggering Event, that the Investors have funded pursuant to their original funding commitment of $85,000,000 from the aggregate initial funding commitment of the Investors of $85,000,000 (the “Funding
Commitment”) by (b) the total Funding Commitment. The portion of the Option that remains outstanding after application of the Forfeiture Percentage shall, subject to the vesting requirements set forth above, be exercisable on or
following the Triggering Event (subject to the Expiration Date of the Option or early termination of the Option pursuant to 

  
 - 1 -

	 	 
Section 4 below). The remainder of the Option shall terminate upon the Triggering Event and the Participant shall have no further rights with respect thereto. For purposes of clarity and by
way of example only, if on the occurrence of the Triggering Event the Option is fully vested and the Forfeiture Percentage is 30% (because the Investors, as of that Triggering Event, have funded only $59,500,000 of the Funding Commitment of
$85,000,000), the Participant will be entitled to exercise 70% of the Option on or after the Triggering Event and the remaining 30% of the Option will terminate at such time. For purposes of this Option Agreement, the term
“Investors” shall mean Domain Partners VIII, L.P., DP VIII Associates, L.P., New Leaf Ventures II, L.P., Canaan VIII, L.P., Aisling Capital III, L.P., and Sofinnova Venture Partners VII, L.P. 

 

	 	•	 	 Cumulative Exercisability. To the extent that the Option is vested and exercisable, the Participant has the right to exercise the Option (to the
extent not previously exercised), and such right shall continue, until the expiration or earlier termination of the Option. 

  

	 	•	 	 No Fractional Shares. Fractional share interests shall be disregarded, but may be cumulated. 

 

	 	•	 	 Minimum Exercise. No fewer than 100 shares of Common Stock (subject to adjustment under Section 7.3.1 of the Plan) may be purchased at any
one time, unless the number purchased is the total number at the time exercisable under the Option. 

  

	 	•	 	 ISO Value Limit. If the Option is designated as an Incentive Stock Option (an “ISO”), as indicated on the cover page of this
Option Agreement, and if the aggregate fair market value of the shares with respect to which ISOs (whether granted under the Option or otherwise) first become exercisable by the Participant in any calendar year exceeds $100,000, as measured on the
applicable Award Dates, the limitations of Section 5.5.1 of the Plan shall apply and to such extent the Option will be rendered a Nonqualified Stock Option. 

 

	2.	Continuance of Emplovment/Service Required; No Employment/Service Commitment. 

Except as provided in Section 1 of this Agreement, the vesting schedule requires continued employment or service through each
applicable vesting date as a condition to the vesting of the applicable installment of the Option and the rights and benefits under this Option Agreement. Employment or service for only a portion of the vesting period, even if a substantial portion,
will not entitle the Participant to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of employment or services as provided in Section 4 below or under the Plan. 

Nothing contained in this Option Agreement or the Plan constitutes a continued employment or service commitment by the Corporation or any
of its Affiliates, affects the Participant’s status, if he or she is an employee, as an employee at will who is subject to termination without cause, confers upon the Participant any right to remain employed by or in

 
service to the Corporation or any Affiliate, interferes in any way with the right of the Corporation or any Affiliate at any time to terminate such employment or service, or affects the right of
the Corporation or any Affiliate to increase or decrease the Participant’s other compensation. 
  

	3.	Method of Exercise of Option. 

 The Option shall be exercisable by the delivery to the Secretary of the Corporation (or such other person as the Administrator may require pursuant to such administrative exercise procedures as the
Administrator may implement from time to time) of: 
  

	 	•	 	 an executed Exercise Agreement (stating the number of shares of Common Stock to be purchased pursuant to the Option) in substantially the form attached
hereto as Exhibit A or such other form as the Administrator may require from time to time (the “Exercise Agreement”), pursuant to which the Participant will become a party to, and be obligated to comply with the terms and
conditions of that certain Right of First Refusal, Drag-Along and Co-Sale Agreement of Durata Therapeutics, Inc., dated as of December 11, 2009, as amended from time to time, by and among the Corporation and the other parties thereto (the
“Co-Sale Agreement”) and that certain Common Holder Voting Agreement of Durata Therapeutics, Inc., dated as of December 11, 2009, as amended from time to time, by and among the Corporation and the other parties thereto, (the
“Voting Agreement”), unless such requirement to be bound by the Co-Sale Agreement and Voting Agreement is expressly waived by the Administrator; 

 

	 	•	 	 payment in full for the Exercise Price of the shares to be purchased, in cash or by electronic funds transfer to the Corporation, or by certified or
cashier’s check payable to the order of the Corporation subject to such specific procedures or directions as the Administrator may establish; 

  

	 	•	 	 any written statements or agreements required pursuant to Section 7.5.1 of the Plan; 

 

	 	•	 	 satisfaction of the tax withholding provisions of Section 7.6.1 of the Plan; 

The Administrator also may, but is not required to, authorize a non-cash payment alternative specified below at or prior to the time of exercise. In
which case, the Exercise Price and/or applicable withholding taxes, to the extent so authorized, may be paid in full or in part by delivery to the Corporation of: 
  

	 	•	 	 shares of Common Stock already owned by the Participant, valued at their Fair Market Value on the exercise date; and/or 

 

	 	•	 	 if the Common Stock is then registered under the Exchange Act and listed or quoted on a recognized national securities exchange, irrevocable
instructions to a broker to, upon exercise of the Option, promptly sell a sufficient number of shares of Common Stock acquired upon exercise of the Option and deliver to the Corporation the amount necessary to pay the Exercise Price (and, if
applicable, the amount of any related tax withholding obligations); and/or 

  

	 	•	 	 a note meeting the requirements of Section 5.3.3 of the Plan (or, in the case of tax loans, Section 7.6.2 of the Plan).

 An Option will qualify as an ISO only if it meets all of the applicable requirements of the Code. If the
Option is designated as an ISO, the Option may be rendered a Nonqualified Stock Option if the Administrator permits the use of one or more of the non-cash payment alternatives referenced above. 

 

	4.	Early Termination of Option. 

 The Option, to the extent not previously exercised, and all other rights in respect thereof, whether vested and exercisable or not, shall terminate and become null and void prior to the Expiration Date in
the event of: 
  

	 	•	 	 the termination of the Participant’s employment or services as provided in Section 5.6 of the Plan, or 

 

	 	•	 	 the termination of the Option pursuant to Section 7.3 of the Plan. 

All or a portion of the Option is also subject to termination prior to the Expiration Date pursuant to Section 1 of these Terms.

 Notwithstanding any post-termination exercise period provided for herein or in the Plan, an Option will qualify as an ISO
only if it is exercised within the applicable exercise periods for ISOs under, and meets all of the other requirements of, the Code. If the Option is designated as an ISO and is not exercised within the applicable exercise periods for ISOs or does
not meet such other requirements, the Option will be rendered a Nonqualified Stock Option. 
  

	5.	Non-Transferability and Other Restrictions. 

 The Option and any other rights of the Participant under this Option Agreement or the Plan are nontransferable and exercisable only by the Participant, except as set forth in Section 7.2 of the Plan.
Any shares of Common Stock issued on exercise of the Option are subject to substantial restrictions on transfer, and are subject to call, rights of first refusal, and other rights in favor of the Corporation as set forth herein, in the Exercise
Agreement, in the Voting Agreement and in the Co-Sale Agreement (as applicable). The restrictions imposed on any such shares pursuant to the Voting Agreement and the Co-Sale Agreement are in addition to, and not in lieu of, any restrictions and
repurchase rights imposed on such shares pursuant to the Plan and this Option Agreement. 

	6.	Securities Law Compliance. 

 The Participant acknowledges that the Option and the shares of Common Stock are not being registered under the Securities Act, based, in part, in reliance upon an exemption from registration under
Securities and Exchange Commission Rule 701 promulgated under the Securities Act, and a comparable exemption from qualification under applicable state securities laws, as each may be amended from time to time. The Participant, by executing this
Option Agreement, hereby makes the following representations to the Corporation and acknowledges that the Corporation’s reliance on federal and state securities law exemptions from registration and qualification is predicated, in substantial
part, upon the accuracy of these representations: 
  

	 	•	 	 The Participant is acquiring the Option and, if and when he/she exercises the Option, will acquire the shares of Common Stock solely for the
Participant’s own account, for investment purposes only, and not with a view to or an intent to sell, or to offer for resale in connection with any unregistered distribution, all or any portion of the shares within the meaning of the Securities
Act and/or any applicable state securities laws. 

  

	 	•	 	 The Participant has had an opportunity to ask questions and receive answers from the Corporation regarding the terms and conditions of the Option and
the restrictions imposed on any shares of Common Stock purchased upon exercise of the Option. The Participant has been furnished with, and/or has access to, such information as he or she considers necessary or appropriate for deciding whether to
exercise the Option and purchase shares of Common Stock. However, in evaluating the merits and risks of an investment in the Common Stock, the Participant has and will rely upon the advice of his/her own legal counsel, tax advisors, and/or
investment advisors. 

  

	 	•	 	 The Participant is aware that the Option may be of no practical value, that any value it may have depends on its vesting and exercisability as well as
an increase in the Fair Market Value of the underlying shares of Common Stock to an amount in excess of the Exercise Price, and that any investment in common shares of a closely held corporation such as the Corporation is non-marketable,
non-transferable and could require capital to be invested for an indefinite period of time, possibly without return, and at substantial risk of loss. 

  

	 	•	 	 The Participant understands that any shares of Common Stock acquired on exercise of the Option will be characterized as “restricted
securities” under the federal securities laws, and that, under such laws and applicable regulations, such securities may be resold without registration under the Securities Act only in certain limited circumstances, including in accordance with
the conditions of Rule 144 promulgated under the Securities Act, as presently in effect, with which the Participant is familiar. 

  

	 	•	 	 The Participant has read and understands the restrictions and limitations set forth in the Plan, this Option Agreement (including these Terms), the
Exercise Agreement, the Voting Agreement and the Co-Sale Agreement, which are imposed on the Option and any shares of Common Stock which may be acquired upon exercise of the Option. 

 

	 	•	 	 At no time was an oral representation made to the Participant relating to the Option or the purchase of shares of Common Stock and the Participant was
not presented with or solicited by any promotional meeting or material relating to the Option or the Common Stock. 

	7.	Lock-Up Agreement. 

Neither the Participant (nor any permitted transferee) may, directly or indirectly, offer, sell or transfer or dispose of any of the
shares of Common Stock acquired upon exercise of the Option (the “Shares”) or any interest therein (or agree to do any thereof) (collectively, a “Transfer”) during the period commencing as of 14 days prior to and
ending 180 days, or such lesser period of time as the relevant underwriters may permit, after the effective date of a registration statement covering any public offering of the Corporation’s securities of which the Participant has notice. (The
term “Participant” includes, where the context so requires, any permitted direct or indirect transferee of the Participant.) The Participant shall agree and consent to the entry of stop transfer instructions with the Corporation’s
transfer agent against the Transfer of the Corporation’s securities beneficially owned by the Participant and shall confirm the limitations hereunder and under the Exercise Agreement by agreement with and for the benefit of the relevant
underwriters by a lock-up agreement or other agreement in customary form. Notwithstanding anything else herein to the contrary, this Section 7 shall not be construed so as to prohibit the Participant from participating in a registration or a
public offering of the Common Stock with respect to any shares which he or she may hold at that time, provided, however, that such participation shall be at the sole discretion of the Board. 

 

	8.	Limited Call Right; Mandatory Sale; Transfer Restrictions. 

 8.1 Corporation’s Call Right. The Corporation shall have the right (but not the obligation), subject to the terms and conditions of this Section 8, to repurchase in one or more
transactions, and the Participant (or any permitted transferee) shall be obligated to sell any of the Shares acquired upon exercise of the Option at the Repurchase Price (as defined below) (the “Call Right”) in connection with a
termination of the Participant’s employment or services by the Corporation or an Affiliate for Cause (as defined in the Plan). To exercise the Call Right, the Corporation must give written notice thereof to the Participant (the “Call
Notice”) during the Call Period determined under Section 8.4. The Call Notice is irrevocable by the Corporation and must (a) be in writing and signed by an authorized officer of the Corporation, (b) set forth the
Corporation’s intent to exercise the Call Right and contain the total number of Shares to be sold to the Corporation pursuant to the Call Right, and (c) be mailed or delivered in accordance with Section 10. 

8.2 Repurchase Price. The price per Share to be paid by the Corporation upon settlement of the Corporation’s Call Right (the
“Repurchase Price”) shall equal the Fair Market Value of a Share determined as of the date of the Call Notice; provided, however, that if the Participant’s employment or service is terminated by the Corporation or an
Affiliate for Cause, the Repurchase Price shall equal the lesser of (i) the price per Share paid by the Participant to acquire the Shares upon exercise of the Option or (ii) the Fair Market Value of a Share determined as of the date
of the Call Notice. 
 8.3 Closing. The closing of any repurchase under this Section 8 shall be at a date to be
specified by the Corporation, such date to be no later than 30 days after the date of the Call Notice. The aggregate Repurchase Price shall be paid at the closing in the form of a check or by cancellation of money purchase indebtedness against
surrender by the Participant of a stock certificate evidencing the Shares with duly endorsed stock powers. No adjustments (other than pursuant to Section 7.3.1 of the Plan) shall be made to the Repurchase Price for fluctuations in the fair
market value of the Common Stock after the date of the Call Notice. 

 8.4 Call Period; Termination of Call Right. The “Call Period” is the
period of time during which the Call Notice must be delivered to the Participant in the event the Corporation wants to exercise its Call Right. The Call Period as to any particular Shares acquired upon exercise of the Option shall commence on the
later of: 
  

	 	(a)	the Participant’s Severance Date (determined in accordance with the Plan); or 

 

	 	(b)	the date that is six months and one day after the Participant acquired the Shares from the Corporation upon exercise of the Option. 

The Call Period as to any particular Shares acquired upon exercise of the Option shall terminate on the first to occur of: 

 

	 	(x)	twelve (12) months after the later of (i) the Participant’s Severance Date or (ii) the date that the Participant acquired the Shares from the
Corporation upon exercise of the Option; or 

  

	 	(y)	the Public Offering Date. 

8.5 Assignment. Notwithstanding anything to the contrary, the Corporation may assign any or all of its rights under this
Section 8 to one or more stockholders of the Corporation. 
  

	9.	No Stockholder Rights Following Exercise of a Call. 

 If the Participant (or any permitted transferee) holds Shares as to which the Call Right has been exercised (in connection with the termination of the Participant’s employment, service or otherwise),
the Participant shall be entitled to payment in accordance with the provisions of Section 8, but (unless otherwise required by law) shall no longer be entitled to participation in the Corporation or other rights as a stockholder with respect to
the shares subject to the call or repurchase. To the maximum extent permitted by law, the Participant’s rights following the exercise of the Call Right shall, with respect to the call or repurchase and the Shares covered thereby, be solely the
rights that he or she has as a general creditor of the Corporation to receive payment of the amount specified in Section 8, as applicable. 
  

	10.	Notices. 

 Any
notice to be given under the terms of this Option Agreement or the Exercise Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Participant at the address reflected or
last reflected on the Corporation’s payroll records. Any notice shall be delivered in person or shall be enclosed in a properly sealed envelope, addressed as aforesaid, registered or certified, and deposited (postage and registry or
certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government. Any such notice shall be given only when received, but if the Participant is no longer an Eligible Person, shall be deemed to
have been duly given five business days after the date mailed in accordance with the foregoing provisions of this Section 10. 

	11.	Plan. 

 The Option
and all rights of the Participant under this Option Agreement are subject to the terms and conditions of the Plan, incorporated herein by this reference. The Participant agrees to be bound by the terms of the Plan and this Option Agreement
(including these Terms). The Participant acknowledges having read and understood the Plan, the Stock Option Questions & Answers for the Plan, and this Option Agreement. Unless otherwise expressly provided in other sections of this Option
Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not and shall not be deemed to create any rights in the Participant unless such rights are expressly set forth herein or are otherwise in the
sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan after the date hereof. 
  

	12.	Entire Agreement. 

This Option Agreement (including these Terms and together with the form of Exercise Agreement attached hereto) and the Plan together
constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan, this Option Agreement and the Exercise Agreement may be amended
pursuant to Section 7.7 of the Plan. Such amendment must be in writing and signed by the Corporation. The Corporation may, however, unilaterally waive any provision hereof or of the Exercise Agreement in writing to the extent such waiver does
not adversely affect the interests of the Participant hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof. The Voting Agreement and the Co-Sale
Agreement are both outside the scope of the foregoing integration provision as to any shares of Common Stock that may be issued upon exercise of the Option. 
  

	13.	Satisfaction of All Rights to Equity. 

 The Option is in complete satisfaction of any and all rights that the Participant may have (under an employment, consulting, or other written or oral agreement with the Corporation or any of its
Affiliates, or otherwise) to receive (1) stock options or stock awards with respect to the securities of the Corporation or any of its Affiliates, and/or (2) any other equity or derivative security in or with respect to the Corporation or
any of its Affiliates. This Option Agreement supersedes the terms of all prior understandings and agreements, written or oral, of the parties with respect to such matters. The Participant shall have no further rights or benefits under any prior
agreement conveying any right with respect to any security or derivative security in or with respect to the Corporation or any of its Affiliates. The foregoing notwithstanding, this Section 13 shall not adversely affect the Participant’s
rights under any prior stock option or stock award agreement under the Plan (provided such agreement is expressly labeled as a stock option or stock award agreement under the Plan and is similar in form to this Option Agreement) which has been
signed by an authorized officer of the Corporation. 
  

	14.	Governing Law; Limited Rights; Severability. 

 14.1 Delaware Law; Construction. This Option Agreement and the Exercise Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without regard
to conflict of law principles thereunder. The terms of the 

 
Option grant have resulted from the negotiations of the parties and each of the parties has had an opportunity to obtain and consult with its own counsel. The language of all parts of the Plan,
this Option Agreement (including these Terms) and the Exercise Agreement shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against either of the parties. 

14.2 Limited Rights. The Participant has no rights as a stockholder of the Corporation with respect to the Option as set forth in
Section 7.8 of the Plan. The Option does not place any limit on the corporate authority of the Corporation as set forth in Section 7.15 of the Plan. 
 14.3 Severability. If a court of competent jurisdiction determines that any portion of this Option Agreement, the Plan, or the Exercise Agreement is in violation of any statute or public policy,
then only the portions of this Option Agreement, the Plan, or the Exercise Agreement, as applicable, which violate such statute or public policy shall be stricken, and all portions of this Option Agreement, the Plan, and the Exercise Agreement which
do not violate any statute or public policy shall continue in full force and effect. Furthermore, it is the parties’ intent that any court order striking any portion of this Option Agreement, the Plan, and/or the Exercise Agreement should
modify the stricken terms as narrowly as possible to give as much effect as possible to the intentions of the parties hereunder. 
 14.4 Stockholder Approval. Notwithstanding anything else contained herein to the contrary, the Option and all rights of the Participant under this Option Agreement are subject to approval of the
Plan by the Corporation’s stockholders (such approval to be obtained in accordance with the terms of the Plan, the Corporation’s Bylaws, and applicable law) within 12 months after the Effective Date of the Plan. 

(Remainder of Page Intentionally Left Blank) 

 EXHIBIT A 
 DURATA THERAPEUTICS, INC. 
 STOCK INCENTIVE PLAN 

OPTION EXERCISE AGREEMENT 
 The undersigned (the “Purchaser”) hereby irrevocably elects to exercise his/her right, evidenced by that certain Stock Option Agreement dated as of
                     (the “Option Agreement”) under the Durata Therapeutics, Inc. Stock Incentive Plan (the
“Plan”), as follows: 
  

	 	•	 	 the Purchaser hereby irrevocably elects to purchase
                     shares of Common Stock, par value $0.01 per share (the “Shares”), of Durata Therapeutics, Inc., a Delaware
corporation (the “Corporation”), and 

  

	 	•	 	 such purchase shall be at the price of $             per share, for an aggregate amount of
$             (subject to applicable withholding taxes pursuant to Section 7.6.1 of the Plan). 

Capitalized terms are defined in the Plan if not defined herein. 

1. Delivery of Share Certificate. The Purchaser requests that a certificate representing the Shares be registered to Purchaser and
delivered to:                     . 
 2. Investment Representations. The Purchaser acknowledges that the sale of the Shares by the Purchaser is restricted by Securities and Exchange Commission Rule 701. The Purchaser hereby affirms as
made as of the date hereof the representations in Section 6 of the “Terms and Conditions of Stock Option” (which are attached to and a part of the Option Agreement, the “Terms”) and such representations are
incorporated herein by this reference. The Purchaser represents that he/she has no need for liquidity in this investment, has the ability to bear the economic risk of this investment, and can afford a complete loss of the purchase price for the
Shares. 
 The Purchaser also understands and acknowledges (a) that the certificates representing the Shares will be
legended as provided for in Section 7.5.3 of the Plan, and (b) that the Corporation has no obligation to register the Shares or file any registration statement under federal or state securities laws. 

3. Limitation on Disposition and Other Restrictions. The Shares are subject to and the Purchaser hereby agrees to the following
terms and conditions of the sale of the Shares to the Purchaser: 
  

	 	•	 	 any transfer of the Shares must comply with the restrictions on transfer set forth in Section 7.2 of the Plan and all applicable laws as set forth
in Section 7.5 of the Plan; 

	 	•	 	 the Shares are subject to, and following any otherwise permitted transfer of the Shares, the Shares shall remain subject to and the transferee shall be
bound by, the lock-up provisions set forth in Section 7 of the Terms, the Corporation’s call right set forth in Section 8 of the Terms, the share legend requirements of Section 7.5.3 of the Plan, the foregoing provisions of this
Section 3, and additional restrictions as set forth in the Voting Agreement and the Co-Sale Agreement; and 

  

	 	•	 	 as a condition to any otherwise permitted transfer of the Shares, the Corporation may require the transferee to execute a written agreement, in a form
acceptable to the Administrator, that the transferee acknowledges and agrees to the foregoing terms and restrictions imposed on the Shares. 

 4. Joinder to Co-Sale Agreement and Voting Agreement. The Purchaser understands that certain holders of preferred stock of the Corporation (“Investors”) have entered into the
Stockholders and Subscription Agreement of the Corporation dated as of December 11, 2009, by and among the Corporation and the Stockholders named therein (as the same may hereafter be amended, the “Stockholders Agreement”), and
has been informed by the Corporation that it is a condition to the Corporation’s issuance of any securities to the Purchaser that the Purchaser agree to be bound by the Right of First Refusal, Drag Along and Co-Sale Agreement dated as of
December 11, 2009, by and among the Corporation, the Investors listed on Schedule A thereto and the Common Holders listed on Schedule B thereto (the “Co-Sale Agreement” as the same may be amended) and the Common Holder Voting
Agreement by and among the Corporation and the Investors and the Common Holders, and the Stockholders named therein (as the same may be amended, the “Voting Agreement”) and to make the additional acknowledgments and agreements under
this Section 4. By executing and delivering this Agreement to the Corporation, the Purchaser hereby agrees to become a party to, to be bound by, and to comply with the provisions of (a) the Co-Sale Agreement, and (b) the Voting
Agreement, in the same manner as if the Purchaser were an original signatory to such agreements. The Purchaser agrees that the Purchaser shall be a Common Holder, as such term is defined in each of the Voting Agreement and Co-Sale Agreement. For the
avoidance of doubt, the Purchaser shall not receive any rights under the Stockholders Agreement. Copies of the Co-Sale Agreement and the Voting Agreement are attached hereto as Exhibits 1 and 2, respectively. 

In addition to the foregoing, the Purchaser further acknowledges and agrees, for the benefit of the Corporation and each Investor, that
(i) subject to the Delaware General Corporation Law, when an Investor takes any action under the Stockholders Agreement to give or withhold its consent, such Investor shall have no duty (fiduciary or other) to consider the interests of the
Corporation, its subsidiaries or other security holders of the Corporation and may act exclusively in its own interests and shall only have the duty to act in good faith, (ii) to the extent not prohibited by antitrust, competition or any other
applicable law, the Purchaser hereby agrees and acknowledges that each director of the Corporation designated by an Investor may share confidential, non-public information about the Corporation and its subsidiaries with the Investor, subject to the
obligation of the director of the Corporation and Investor to hold such shares in confidence pursuant to the Stockholders Agreement, and (iii) the Purchaser shall have no authority to manage the business or affairs of the Corporation or
contract for or incur on behalf of the Corporation any debts, liabilities or other actions, and no such actions of the undersigned shall be binding on the Corporation. 

 5. Plan and Option Agreement. The Purchaser acknowledges that all of his/her rights
are subject to, and the Purchaser agrees to be bound by, all of the terms and conditions of the Plan and the Option Agreement (including the Terms and the Stock Option Questions & Answers for the Plan), both of which are incorporated herein
by this reference. If a conflict or inconsistency between the terms and conditions of this Exercise Agreement and of the Plan or the Option Agreement shall arise, the terms and conditions of the Plan and/or the Option Agreement shall govern. The
Purchaser acknowledges receipt of a copy of all documents referenced herein (including the Terms) and acknowledges reading and understanding these documents and having an opportunity to ask any questions that he/she may have had about them.

 6. Entire Agreement. This Exercise Agreement, the Option Agreement (including the Terms), and the Plan together
constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan, the Option Agreement and this Exercise Agreement may be amended
pursuant to Section 7.7 of the Plan. Such amendment must be in writing and signed by the Corporation. The Corporation may, however, unilaterally waive any provision hereof or of the Option Agreement in writing to the extent such waiver does not
adversely affect the interests of the Purchaser hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof. The Voting Agreement and the Co-Sale Agreement
are both outside the scope of the foregoing integration provision as to any Shares that may be issued upon exercise of the Option. 
 7. Notice of Sale of ISO Shares. If the Shares are being acquired upon exercise of an Option intended to qualify as an Incentive Stock Option, the Purchaser agrees that, upon any sale or other
transfer of the Shares within either one year of the date that they are acquired by the Purchaser or two years after the Award Date set forth in the Option Agreement, the Purchaser shall provide the notice required under Section 5.5.3 of the
Plan. 
  

							
	 “PURCHASER”
  

 
	 		 	 ACCEPTED BY:
 DURATA THERAPEUTICS, INC.,
 a Delaware corporation

	Signature	 		 		 	
	  
	 		 	By:	 	  

	Print Name	 		 	Its:	 	  

	  
	 		 		 	
	Date	 		 	(To be completed by the corporation after the price (including applicable withholding taxes), value (if applicable) and receipt of funds is
verified.)

 CONSENT OF SPOUSE 
 I, [                    ], spouse of
[                    ] acknowledge that I have read (a) the Co-Sale Agreement, (b) the Voting Agreement, and (c) this Option Exercise
Agreement (together with the Co-Sale Agreement and the Voting Agreement, the “Agreements”), and that I know the contents of the Agreements. I am aware that (i) the Co-Sale Agreement contains provisions providing certain rights to
certain other holders of Capital Stock of the Company upon a Proposed Common Holder Transfer of shares of Transfer Stock of the Company which my spouse may own, including any interest I might have therein, and (ii) the Common Holder Voting
Agreement contains provisions regarding the voting and transfer of shares of Capital Stock of the Company which my spouse may own, including any interests I might have therein. 

I hereby agree that my interest, if any, in (i) any shares of Transfer Stock of the Company, subject to the Co-Sale Agreement, and
(ii) any shares of Capital Stock, subject to the Voting Agreement, shall be irrevocably bound by the Agreements and further understand and agree that any community property interest I may have in such shares of Transfer Stock of the Company or
Capital Stock of the Company shall be similarly bound by the Agreements. I am aware that the legal, financial and related matters contained in the Agreements are complex and that I am free to seek independent professional guidance or legal counsel
with respect to this Consent of Spouse. I have either sought such guidance or legal counsel or determined after reviewing the Agreements carefully that I will have elected to waive such right. Dated as of the
         day of             , 20    . 

 

	
	  

	Signature
	
	  

	Print Name

 EXHIBIT 1 
 CO-SALE AGREEMENT 

 EXHIBIT 2 
 VOTING AGREEMENT 

 EXHIBIT 3 
 DEFINITION OF QUALIFYING CHANGE OF CONTROL 
 “Qualifying Change in Control” shall mean
the consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any corporation or other entity a majority of whose outstanding voting stock or voting power is
beneficially owned directly or indirectly by the Company (a “Subsidiary”), a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any
of its Subsidiaries (each, a “Business Combination”), in each case that results in: (a) the sale or other disposition by the Investors of at least 65% of their Investment in the Company, (b) the Investors ceasing to beneficially
own, directly or indirectly, more than 50% of the combined voting power of the voting securities entitled to vote generally in the election of directors (on a fully diluted basis) of the entity resulting from such Business Combination (including,
without limitation, an entity that, as a result of such transaction, owns the Company or all or substantially all of the Company’s assets directly or through one or more subsidiaries), and (c) the total proceeds received by each of the
Investors in the form of cash and/or readily marketable securities at the closing of such Business Combination in respect of such Business Combination from the sale of their Investment equals or exceeds an amount equal to the product of
(i) such Investor’s Invested Capital and (ii) 2.0. For purposes of clarity, such proceeds (in the form of cash and/or readily marketable securities) received by an Investor in respect of such a Business Combination from the sale of
its Investment shall exclude for this purpose: (1) any future consideration or potential future consideration (other than proceeds in the form of cash and/or readily marketable securities paid at or within 30 days following the closing of
the Business Combination), (2) any consideration paid or payable in respect of stock, options, warrants, other rights to acquire shares of capital stock of the Company or other equity securities of the Company not held by the Investor, and
(3) any non-cash consideration other than readily marketable securities. 

 EXHIBIT C 
 JOINDER TO CO-SALE AGREEMENTInvestor Rights Agreement,dated  December 11, 2009

 Exhibit 10.6 
 INVESTOR RIGHTS AGREEMENT 
 By and Among 

DURATA THERAPEUTICS, INC. 
 and 
 THE HOLDERS OF PREFERRED SHARES THEREOF 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
			
	 1.
	  	 DEFINITIONS; RULES OF CONSTRUCTION
	  	 	1	  
				
		  	 (a)
	  	 Definitions
	  	 	1	  
		  	 (b)
	  	 Rules of Construction
	  	 	3	  
			
	 2.
	  	 REGISTRATION RIGHTS
	  	 	4	  
				
		  	 (a)
	  	 Demand Registration
	  	 	4	  
		  	 (b)
	  	 Designation of Joint Counsel
	  	 	6	  
			
	 3.
	  	 PIGGYBACK REGISTRATIONS
	  	 	6	  
				
		  	 (a)
	  	 Registration of the Company’s Securities
	  	 	6	  
		  	 (b)
	  	 Right to Terminate Registration
	  	 	6	  
		  	 (c)
	  	 Underwriting Requirements
	  	 	7	  
		  	 (d)
	  	 Exempt Transactions
	  	 	7	  
			
	 4.
	  	 PROCEDURES
	  	 	8	  
				
		  	 (a)
	  	 Registration Procedures and Obligations
	  	 	8	  
		  	 (b)
	  	 Information from Holder
	  	 	9	  
		  	 (c)
	  	 Expenses of Registration
	  	 	9	  
		  	 (d)
	  	 Delay of Registration
	  	 	10	  
			
	 5.
	  	 INDEMNIFICATION
	  	 	10	  
				
		  	 (a)
	  	 Company Indemnity
	  	 	10	  
		  	 (b)
	  	 Holder Indemnity
	  	 	10	  
		  	 (c)
	  	 Notice of Indemnification Claim
	  	 	11	  
		  	 (d)
	  	 Contribution
	  	 	11	  
		  	 (e)
	  	 Underwriting Agreement
	  	 	12	  
		  	 (f)
	  	 Survival
	  	 	12	  
			
	 6.
	  	 ADDITIONAL UNDERTAKINGS
	  	 	12	  
				
		  	 (a)
	  	 Reports under the Exchange Act
	  	 	12	  
		  	 (b)
	  	 Limitations on Subsequent Registration Rights
	  	 	12	  
		  	 (c)
	  	 “Market Stand-Off” Agreement
	  	 	13	  
		  	 (d)
	  	 Termination of Registration Rights
	  	 	13	  
		  	 (e)
	  	 Assignment of Registration Rights and Information Rights
	  	 	13	  
		  	 (f)
	  	 Qualified Small Business Stock
	  	 	14	  

  
 i 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	  	 	  	 	  	Page	 
			
	 7.
	  	 RESTRICTIVE LEGENDS
	  	 	14	  
			
	 8.
	  	 REMEDIES
	  	 	14	  
			
	 9.
	  	 MISCELLANEOUS
	  	 	15	  
				
		  	 (a)
	  	 Conflicting Agreements
	  	 	15	  
		  	 (b)
	  	 Amendment; Waiver; or Termination
	  	 	15	  
		  	 (c)
	  	 Notices
	  	 	15	  
		  	 (d)
	  	 Governing Law
	  	 	16	  
		  	 (e)
	  	 Service of Process; Consent to Jurisdiction
	  	 	16	  
		  	 (f)
	  	 Representation by Counsel
	  	 	16	  
		  	 (g)
	  	 Waiver
	  	 	16	  
		  	 (h)
	  	 Recapitalizations, Exchanges, Etc
	  	 	16	  
		  	 (i)
	  	 Severability
	  	 	17	  
		  	 (j)
	  	 Entire Agreement
	  	 	17	  
		  	 (k)
	  	 Successors and Assigns
	  	 	17	  
		  	 (l)
	  	 Further Assurances
	  	 	17	  
		  	 (m)
	  	 Multiple Counterparts
	  	 	17	  
		  	 (n)
	  	 Not for Benefit of Third Parties
	  	 	17	  
		  	 (o)
	  	 Attorneys’ Fees
	  	 	17	  
		  	 (p)
	  	 Titles and Headings
	  	 	17	  
		  	 (q)
	  	 No Interpretation Against Drafter
	  	 	17	  

  
 ii 

 INVESTOR RIGHTS AGREEMENT 

THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is dated as of December 11, 2009, and is by and among
(i) Durata Therapeutics, Inc., a Delaware corporation (the “Company”), and (ii) the holders of Preferred Shares of the Company listed from time to time on the attached Schedule A (each an “Investor”
and collectively, with their successors, transferees and assigns, the “Investors”). 
 THE PARTIES ENTER INTO
THIS AGREEMENT ON THE BASIS OF THE FOLLOWING FACTS, INTENTIONS AND UNDERSTANDINGS: 
 A. On the date hereof, the Investors are
entering into that certain Stockholders and Subscription Agreement dated as of December 11, 2009, by and among the Company and the respective Investors (the “Stock Purchase Agreement”), pursuant to which the Investors are
purchasing Preferred Shares. 
 B. It is a condition to the obligations of the Investors under the Stock Purchase Agreement that
this Agreement shall be executed by the parties hereto, and the parties are willing to execute this Agreement and be bound by the provisions hereof. 
 NOW, THEREFORE, in consideration of the mutual covenants and premises contained in this Agreement and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the parties hereto agree as follows: 
 1. Definitions: Rules of Construction. 

(a) Definitions. Capitalized terms used herein are defined in this Section 1. unless otherwise defined herein. 

1.1 “Accredited Investor” has the meaning set forth for such term in Regulation D under the Securities Act. 

1.2 “Affiliate” means (a) with respect to any individual, (i) a spouse or descendant of such individual,
(ii) any trust or family partnership whose beneficiaries shall solely be such individual and/or such individual’s spouse and/or any Person related by blood, marriage or adoption to such individual or such individual’s spouse, and
(iii) the estate of such individual; and (b) with respect to any Person which is not an individual, any other Person that, directly or indirectly through one or more intermediaries controls (as defined in the Securities Act), is controlled
by, or is under common control with, such Person and/or one or more Affiliates thereof. 
 1.3 “Board” means
the Board of Directors of the Company. 
 1.4 “Common Shares” means shares of Common Stock, $0.01 par value of
the Company. 
 1.5 “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any similar
federal law then in force. 

  
 1 

 1.6 “Form S-3” means such form under the Securities Act as in effect on the
date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.7 “GAAP” means U.S. generally accepted accounting principles. 

1.8 “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in
accordance with Section 6(e) hereof. 
 1.9 “IPO” means the initial underwritten public offering of
the Common Shares pursuant to the Securities Act. 
 1.10 “Initiating Holders” mean, with respect to a request
duly made under Section 2 to Register any Registrable Securities, the Holders initiating such request 
 1.11
“Person” shall be construed broadly and shall include, without limitation, an individual, a partnership, an investment fund, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint
venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. 

1.12 “Preferred Shares” means shares of Series A Preferred Stock, $0.01 par value of the Company. 

1.13 “Public Sale” means any sale effected as part of or after the first Qualified IPO by the Company pursuant to a
registered public offering under the Securities Act or any sale to the public pursuant to Rule 144 under the Securities Act or any successor rule. 
 1.14 “Qualified IPO” means an underwritten public offering of the Common Shares pursuant to the Securities Act at a public offering price (prior to underwriter commissions and expenses)
of at least $3.00 per share (as adjusted for any dividends, combinations or splits with respect to such shares) and with gross proceeds (prior to underwriter commissions and expenses) of at least $50,000,000. 

1.15 “Registrable Securities” means (i) the Senior Conversion Shares, (ii) other Securities which by their
terms are exercisable or exchangeable for or convertible into either Senior Conversion Shares (including any warrant, right or convertible debt securities), and (iii) any other Securities issued as (or issuable upon the conversion or exercise of any
warrant, right or other Security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the Securities described in clause (i), or (ii). 

1.16 “Registrable Securities Then Outstanding” means the number of shares of common stock of the Company that are
Registrable Securities and (i) are then issued and outstanding, or (ii) are then issuable pursuant to the exercise or conversion of then outstanding and exercisable Securities of the Company. 

1.17 “Registration” means a registration effected by preparing and filing a Registration Statement and the declaration
or ordering of the effectiveness of that Registration Statement; and the terms “Register” and “Registered” have meanings concomitant with the foregoing. 

  
 2 

 1.18 “Registration Statement” means a registration statement prepared on
Form S-1 or S-3 under the Securities Act. 
 1.19 “Restricted Securities” means, at any point in time, any
Securities issued by the Company which have not theretofore been transferred in a Public Sale. 
 1.20 “Senior
Conversion Shares” mean (i) the Common Shares issued or issuable upon the conversion of Series A Preferred Shares held by the Investors, or (ii) any other Common Shares issued as (or issuable upon the conversion or exercise of any
warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares described in clause (i). 

1.21 “Securities” means, with respect to any Person, such Person’s capital shares or other equity interests or any
options, warrants or other securities that are directly or indirectly convertible into, or exercisable or exchangeable for, such Person’s capital shares or other equity or equity linked interests, including phantom stock and stock appreciation
rights. Whenever a reference herein to Securities is referring to any derivative Securities, the rights of an Investor shall apply to such derivative Securities and all underlying Securities directly or indirectly issuable upon conversion, exchange
or exercise of such derivative securities. 
 1.22 “SEC” shall mean the United States Securities and Exchange
Commission. 
 1.23 “Securities Act” means the Securities Act of 1933, as amended, or any similar federal law
in effect. 
 1.24 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer
taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of special counsel to the Holders as provided in Section 4(c)). 

1.25 “Subsidiary” shall mean any other Person (a) whose Securities having a majority of the general voting power in
electing the board of directors or equivalent governing body of such other Person are, at the time as of which any determination is being made, owned by such Person either directly or indirectly through one or more other entities constituting
Subsidiaries or (b) more than a fifty percent (50%) interest in the profits or capital of whom is, at the time as of which any determination is being made, owned by such Person either directly or indirectly through one or more other
entities constituting Subsidiaries. 
 1.26 “Violation” has the meaning set forth in Section 5(a)(i).

 (b) Rules of Construction. 
 (i) The use in this Agreement of the term “including” means “including, without limitation.” The words “herein,” “hereof,” “hereto,” “hereunder”
and other words of similar import refer to this Agreement as a whole, including the schedules and exhibits, 

  
 3 

 
as the same may from time to time be amended or supplemented, and not to any particular section, subsection, paragraph, subparagraph or clause contained in this Agreement All references to
sections, schedules and exhibits mean the sections of this Agreement and the schedules and exhibits attached to this Agreement. 
 (ii) The title of and the section and paragraph headings in this Agreement are for convenience of reference only and shall not govern the interpretation of any of the terms or provisions of this
Agreement. 
 (iii) The use herein of the masculine, feminine or neuter forms shall also denote the other forms, as the context
may require in each case. 
 (iv) Where specific language is used to clarify by example a general statement contained herein,
such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates. The language used in this Agreement has been chosen by the parties to express their mutual intent If
an ambiguity or question of intent or interpretation arises, then this Agreement will be construed as if drafted jointly by the parties to this Agreement and no presumption or burden of proof will arise favoring or disfavoring any party to this
Agreement by virtue of the authorship of any of the provisions of this Agreement. 
 2. Registration Rights. The Company
covenants and agrees as follows: 
 (a) Demand Registration. 

(i) Registration Other Than on Form S-3. Subject to the terms of this Agreement at any time after the earlier of (i) three
(3) years after the date of this Agreement (ii) such date as the Investors have purchased in the aggregate Eighty-Five Million Dollars ($85,000,000) of Preferred Shares pursuant to the Stock Purchase Agreement, and (iii) the date that is
one hundred eighty (180) days after the closing of an IPO, Initiating Holders holding 75% of Registrable Securities Then Outstanding may request the Company in writing to effect the Registration of such Registrable Securities having an
aggregate offering price to the public of not less than Ten Million Dollars ($10,000,000). Upon receipt of such a request, the Company shall: (a) promptly give written notice of the proposed Registration to all other Holders; and (b) as soon as
reasonably practicable, use its commercially reasonable efforts to cause the Registrable Securities specified in such request, together with any Registrable Securities of any Holder who requests in writing to join such Registration within fifteen
(15) days after the Company’s delivery of written notice, to be Registered and/or qualified for sale and distribution in such jurisdictions as the Initiating Holders holding 75% of Registrable Securities Then Outstanding may reasonably
request. The Company shall not be obligated to effect, or to take any action to effect, any Registration pursuant to this Section 2(a)(i): (x) after the Company has effected two (2) Registrations pursuant to this Section
2(a)(i) and such Registrations have been declared or ordered effective; or (y) if the Initiating Holders holding 75% of Registrable Securities Then Outstanding propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Section 2(a)(ii) below. 

  
 4 

 (ii) Registration on Form S-3. Subject to the terms of this Agreement, Holders of
Registrable Securities may request the Company in writing to file a Registration Statement on Form S-3 (or any successor form to Form S-3, or any comparable form for Registration) for a public offering of Registrable Securities for which the
reasonably anticipated aggregate price to the public, net of Selling Expenses, would exceed One Million Dollars ($1,000,000), and the Company is entitled to use Form S-3 or a comparable form to Register the requested Registrable Securities. Upon
receipt of such a request the Company shall: (a) promptly give written notice of the proposed Registration to all other Holders and (b) as soon as practicable, use its reasonable best efforts to cause the Registrable Securities specified in the
request, together with any Registrable Securities of any Holder who requests in writing to join such Registration within fifteen (15) days after the Company’s delivery of written notice, to be Registered and qualified for sale and
distribution in such jurisdictions as the Initiating Holders may reasonably request 
 (iii) Rights of Deferral.

 (A) The Company shall not be obligated to Register or qualify Registrable Securities pursuant to this Section 2(a):

 (1) in any jurisdiction in which the Company would be required to execute a general consent to service of process in
effecting such Registration or qualification, unless the Company is already subject to service of process in such jurisdiction; 
 (2) if, within thirty (30) days after the receipt of any request of the Holders to Register any Registrable Securities under Section 2(a)(i) or Section 2(a)(ii), the Company
gives notice to the Initiating Holders of its bona fide intention to effect the filing for its own account of a Registration Statement with the SEC within ninety (90) days of the date of such notice from the Company (other than a registration
of securities in a transaction under Rule 145 of the Securities Act or an offering solely to employees), provided, however, that the Company is using commercially reasonable efforts to cause that Registration Statement to become
effective; or 
 (3) within six (6) months immediately following the effective date of any Registration Statement
pertaining to an IPO. 
 (B) If, after receiving a request from the Holders pursuant to Section 2(a)(i) or
Section 2(a)(ii), the Company furnishes to the Holders a certificate signed by an officer of the Company stating that, in the good faith judgment of the Board, it would be seriously detrimental to the Company or its shareholders for a
Registration Statement to be filed in the near future, the Company’s obligation to use its commercially reasonable efforts to file a Registration Statement shall be deferred for a period not to exceed one hundred and twenty (120) days from
the receipt of any request duly submitted by the Holders under Section 2(a)(i) or Section 2(a)(ii) to Register Registrable Securities; provided, however, that the Company shall not exercise the right contained
in this Section 2(a)(iii)(B) more than once in any twelve (12)-month period. 

  
 5 

 (iv) Underwritten Offerings. If, in connection with a request to Register
Registrable Securities under Section 2(a)(i) or Section 2(a)(ii), the Initiating Holders seek to distribute such Registrable Securities in an underwriting, they shall so advise the Company as a part of the request, and the
Company shall include such information in the written notice to the other Holders described in Sections 2(a)(i) and 2(a)(ii). In such event, the right of any Holder to include its Registrable Securities in such Registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by Initiating Holders representing a majority of the
Registrable Securities Then Outstanding held by the Initiating Holders) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with
the underwriter or underwriters selected for such underwriting by the Company (which underwriter or underwriters shall be reasonably acceptable to the Initiating Holders representing a majority of the Registrable Securities Then Outstanding held by
the Initiating Holders). Notwithstanding any other provision of this Agreement, if the managing underwriter advises the Company that marketing factors (including, without limitation, the aggregate number of securities requested to be Registered and
the general condition of the market) require a limitation of the number of Securities to be underwritten, the underwriters may exclude some of the Registrable Securities from the underwriting if so justified after excluding any other Securities from
the underwriting. If a limitation of the number of Registrable Securities is required pursuant to this Section 2(a)(iv), the number of Registrable Securities that may be included in the underwriting by the selling Holders shall be
allocated among such Holders, in proportion, as nearly as practicable, to the respective amounts of Registrable Securities which the Holders would otherwise be entitled to include in the Registration. Any Registrable Securities excluded or withdrawn
from such underwriting shall be withdrawn from the Registration. 
 (b) Designation of Joint Counsel. In connection with
any Registration under this Section, the Initiating Holders holding a majority of Registrable Securities then held by the Initiating Holders shall mutually agree on counsel to represent the Holders in such Registration. 

3. Piggyback Registrations. 
 (a) Registration of the Company’s Securities. Subject to Section 3(c), if the Company proposes to Register for its own account any of its Securities in connection with the public
offering of such securities, the Company shall promptly give each Holder written notice of such Registration and, upon the written request of any Holder given within twenty (20) days after delivery of such notice, the Company shall use its
commercially reasonable efforts to include in such Registration any Registrable Securities thereby requested by such Holder. 

(b) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any Registration initiated by it
under Section 3(a) prior to the effectiveness of such Registration, whether or not any Holder has elected to participate therein. The expenses of such withdrawn Registration shall be borne by the Company in accordance with
Section 4(c). 

  
 6 

 (c) Underwriting Requirements. 

(i) In connection with any offering involving an underwriting of the Company’s Securities, the Company shall not be required to
Register the Registrable Securities of a Holder under this Section 3 unless such Holder’s Registrable Securities are included in the underwriting and such Holder enters into an underwriting agreement in customary form with the
underwriters selected by the Company and setting forth such terms for the underwriting as have been agreed upon between the Company and the underwriters. In the event the underwriters advise the Holders seeking Registration of Registrable Securities
pursuant to this Section 3 in writing that market factors (including, without limitation, the aggregate number of Registrable Securities requested to be Registered, the general condition of the market and the status of the persons
proposing to sell securities pursuant to the Registration) require a limitation of the number of Securities to be underwritten, the underwriters may exclude Registrable Securities from the Registration and underwriting if so justified after
excluding any other Securities (except for Securities to be offered by the Company) from the Registration and underwriting, so long as the amount of Registrable Securities included in such offering is not reduced below 30% of the total number of
securities included in the offering, unless such offering is the IPO, in which case all Registrable Securities may be excluded. 
 (ii) If a limitation on the number of Registrable Securities is required pursuant to paragraph (a), the number of Registrable Securities that may be included in the Registration and underwriting by
selling Holders shall be allocated first among such Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities that are Senior Conversion Shares which the Holders would otherwise be entitled to include in
the Registration. 
 (iii) If any Holder disapproves of the terms of any underwriting, the Holder may elect to withdraw
therefrom by written notice to the Company and the underwriters delivered at least seven (7) days prior to the effective date of the Registration Statement. Any Registrable Securities excluded or withdrawn from the underwriting shall be
withdrawn from the Registration. 
 (d) Exempt Transactions. The Company shall have no obligation to Register any
Registrable Securities under this Section 3 in connection with a Registration by the Company (i) relating solely to the sale of securities to participants in a Company stock plan, (ii) relating to a corporate reorganization or other
transaction under Rule 145 promulgated under the Securities Act (or comparable provision under the laws of another jurisdiction, as applicable), or (iii) on any form that does not include substantially the same information as would be required
to be included in a Registration Statement covering the sale of the Registrable Securities. 

  
 7 

 4. Procedures. 

(a) Registration Procedures and Obligations. Whenever required under this Agreement to effect the Registration of any Registrable
Securities held by the Holders, the Company shall, as expeditiously as possible: 
 (i) Prepare and file with the SEC a
Registration Statement with respect to those Registrable Securities and use its commercially reasonable efforts to cause that Registration Statement to become effective, and, upon the request of the Holders holding a majority of the Registrable
Securities Registered thereunder, keep the Registration Statement effective for a period that is the shorter of up to one hundred twenty (120) days or until the distribution contemplated in the Registration Statement has been completed;
provided, however, that: (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of
an underwriter of ordinary shares (or other securities) of the Company; and (ii) in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such one hundred twenty
(120) day period shall be extended, if necessary, to keep the Registration Statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or
delayed basis, and provided further that applicable rules under the Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which (1) includes any prospectus required by
Section 10(a)(3) of the Securities Act, or (2) reflects facts or events representing a material or fundamental change in the information set forth in the Registration Statement, the incorporation by reference of information required to be
included in (1) or (2) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the Registration Statement; 
 (ii) Prepare and file with the SEC amendments and supplements to that Registration Statement and the prospectus used in connection with the Registration Statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all securities covered by the Registration Statement. 

(iii) Furnish to the Holders the number of copies of a prospectus, including a preliminary prospectus, required by the Securities Act,
and any other documents as they may reasonably request to facilitate the disposition of Registrable Securities owned by them. 

(iv) Use its commercially reasonable efforts to Register and qualify the securities covered by the Registration Statement under the
securities laws of any jurisdiction, as reasonably requested by the Holders, provided, however, that the Company shall not be required to qualify to do business or file a general consent to service of process in any such jurisdictions,
and provided, further, that in the event any jurisdiction in which the securities shall be qualified imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling
shareholders, those expenses shall be payable pro rata by selling shareholders. 
 (v) In the event of any underwritten public
offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of the offering. Each shareholder participating in the underwriting shall also enter into and perform its
obligations under the underwriting agreement. 
 (vi) Notify each Holder of Registrable Securities covered by the Registration
Statement at any time when a prospectus relating thereto is required to be delivered 

  
 8 

 
under the Securities Act or of (i) the issuance of any stop transfer order by the SEC in respect to such Registration Statement, or (ii) the happening of any event as a result of which any
prospectus included in the Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the
light of the circumstances then existing. The Company will amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in the light of the circumstances then existing. 
 (vii) Provide a
transfer agent and registrar for all Registrable Securities Registered pursuant to the Registration Statement and, where applicable, a CUSIP number for all those Registrable Securities, in each case not later than the effective date of the
Registration. 
 (viii) Furnish, at the request of any Holder requesting Registration of Registrable Securities pursuant to
this Agreement, on the date that such Registrable Securities are delivered for sale in connection with a Registration pursuant to this Agreement, (i) an opinion, dated the date of the sale, of counsel to the Company for the purposes of the
Registration, in form and substance as is customarily given to underwriters in an underwritten public offering, and (ii) a comfort letter dated the date of the sale, from the independent certified public accountants of the Company, in form and
substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters. 
 (ix) Take all reasonable action necessary to list the Registrable Securities on the primary exchange upon which the Company’s securities are then traded. 

(b) Information from Holder. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Agreement with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of such
securities as shall be required to effect the Registration of such Holder’s Registrable Securities. 
 (c) Expenses of
Registration. Except as provided below, all expenses, other than Selling Expenses, incurred in connection with Registrations, filings or qualifications pursuant to this Agreement, including, without limitation, all Registration, filing and
qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and expenses of one special counsel for the Holders, shall be borne by the Company. The Company shall not, however, be
required to pay for any expenses of any Registration proceeding begun pursuant to this Agreement if the Registration request is subsequently withdrawn at the request of the Holders representing a majority of the Registrable Securities to be
Registered (in which case all participating Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be thereby Registered in the withdrawn Registration); provided, however, that if at the
time of such withdrawal, the Holders have learned of a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses. 

  
 9 

 (d) Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any Registration as the result of any controversy that may arise with respect to the interpretation or implementation of this Agreement. 

5. Indemnification. 
 (a) Company Indemnity. 
 (i) To the extent permitted by law, the Company
will indemnify and hold harmless each Holder, such Holder’s officers, directors, shareholders, legal counsel and accountants, any underwriter (as defined in the Securities Act) for such Holder and each Person, if any, who controls (as defined
in the Securities Act) such Holder or underwriter against any losses, claims, damages or liabilities (joint or several) to which they may become subject under laws which are applicable to the Company and relate to action or inaction required of the
Company in connection with any Registration, qualification or compliance, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations
(each a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such Registration Statement, including any preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto; (ii) the omission or alleged omission to state in the Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, a material
fact required to be stated therein or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, or any rule or regulation promulgated under the Securities Act The
Company shall reimburse each such Holder, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action. 

(ii) The indemnity agreement contained in this Section 5(a) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such loss,
claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such Registration by any such
Holder, underwriter or controlling person. 
 (b) Holder Indemnity. 

(i) To the extent permitted by law, each selling Holder shall indemnify and hold harmless the Company, its directors, officers,
shareholders, legal counsel and accountants, any underwriter, any other Holder selling securities in connection with such Registration and each Person, if any, who controls (within the meaning of the Securities Act) the Company, such underwriter or
other Holder, against any losses, claims, damages or liabilities 

  
 10 

 
(joint or several) to which any of the foregoing persons may become subject, under the Securities Act, or any rule or regulation promulgated under the Securities Act, insofar as such losses,
claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information
furnished by such Holder expressly for use in connection with such Registration; and each such Holder shall reimburse any person intended to be indemnified pursuant to this Section 5.2, for any legal or other expenses reasonably incurred by
such person in connection with investigating or defending any such loss, claim, damage, liability or action. 
 (ii) The
indemnity contained in this Section 5.2 shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be
unreasonably withheld, conditioned or delayed), and in no event shall any indemnity under this Section 5.2 exceed the net proceeds from the offering received by such Holder. 

(c) Notice of Indemnification Claim. Promptly after receipt by an indemnified party under Section 5.1 or
Section 5.2 of notice of the commencement of any action (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party under Section 5.1 or
Section 5.2, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties. An indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall
have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or
potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 5, but the omission to deliver written notice to the indemnifying party will
not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 5. 

(d) Contribution. If any indemnification provided for in Section 5.1 or Section 5.2 is held by a court of
competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to
the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party, on the one hand, and of the indemnified
party, on the other, in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ 

  
 11 

 
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. In no event shall any amounts contributed by any indemnifying party under this
Section 5.2(d) exceed the net proceeds from the offering received by such indemnifying party. 
 (e) Underwriting
Agreement. To the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the
provisions in the underwriting agreement shall control. 
 (f) Survival. The obligations of the Company and Holders under
this Section 5 shall survive the completion of any offering of Registrable Securities in a Registration Statement under this Agreement, and otherwise. 
 6. Additional Undertakings. 
 (a) Reports under the Exchange Act.
With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any comparable provision of any Applicable Securities Law that may at any time permit a Holder to sell securities of the Company to the
public without Registration or pursuant to a Registration on Form S-3 (or any comparable form in a jurisdiction other than the United States), the Company agrees to: 
 (i) make and keep public information available, as those terms are understood and defined in such Rule 144 (or comparable provision under the Securities Act in any jurisdiction where the Company’s
securities are listed), at all times following ninety (90) days after the effective date of an IPO; 
 (ii) file with the
SEC in a timely manner all reports and other documents required of the Company under all the Securities Act; and 
 (iii) at
any time following ninety (90) days after the effective date of the IPO, promptly furnish to any Holder holding Registrable Securities, upon request (i) a written statement by the Company that it has complied with the reporting
requirements of all the Securities Act at any time after it has become subject to such reporting requirements or, at any time after so qualified, that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (or any form
comparable thereto under the Securities Act of any jurisdiction where the Company’s securities are listed), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents as may be filed by
the Company with the SEC and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without Registration or pursuant to such form.

 (b) Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not,
without the prior written consent of the Holders of a 75% of the Registrable Securities Then Outstanding, enter into any agreement with any holder or prospective holder of any Securities of the Company that would allow such holder or prospective
holder to include such securities in any Registration filed under Section 2 or Section 3, unless 

  
 12 

 
under the terms of such agreement such holder or prospective holder may include such Securities in any such Registration only to the extent that the inclusion of such securities will not reduce
the amount of the Registrable Securities of the Holders that are included. 
 (c) “Market Stand-Off” Agreement.
Each Holder agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing
underwriter (such period not to exceed 180 days, which may be extended if requested by the underwriter to accommodate regulatory restrictions on (a) the publication or other distribution of research reports, and (b) analyst recommendations
and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) to (i) lend, offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Securities (excluding Securities purchased in the IPO or the
public markets), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such Securities except for Registrable Securities included in the IPO;
provided, however, that all officers and directors of the Company and holders of at least one percent (1%) of the Company’s voting securities are similarly bound. The underwriters in connection with the IPO are intended third
party beneficiaries of this Section 6.3 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. To enforce the foregoing covenant, the Company may impose stop-transfer
instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. Each Holder further agrees to execute such agreements as
may be reasonably requested by the underwriters in the IPO as are consistent with this Section 6.3 or necessary to give further effect thereto. If there is any release from such agreement of any Holder’s shares subject to such
restrictions, then each other Holder may sell, transfer or otherwise dispose of an equal percentage of such Holder’s shares originally subject to such restrictions; provided, however, that this provision will not apply to
(a) releases not exceeding 100,000 shares of Registrable Securities (as adjusted for any stock dividends, combinations, splits or the like with respect to such shares) with respect to any single Holder individually or affiliated Holders
collectively, or (b) participating Holders in a secondary Public Sale, in either case, during the market standoff time period. 
 (d) Termination of Registration Rights. No Holder shall be entitled to exercise any Registration rights provided for in Section 2 or Section 3 hereof following the later to
occur of: (i) six (6) years following the consummation of the IPO or (ii) at such time as all Registrable Securities held by such Holder (and any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144)
can be sold in a single transaction pursuant to Rule 144 promulgated under the Securities Act. 
 (e) Assignment of
Registration Rights and Information Rights. The right to cause the Company to Register Registrable Securities pursuant to this Agreement and information and inspection rights set forth in Section 7 below may be assigned by a Holder
to a transferee or assignee of such securities that (i) is an Affiliate of a Holder, (ii) is a member of a Holder’s family or a trust for the benefit of an individual Holder or family member thereof,

  
 13 

 
(iii) is a partner or retired partner of any holder that is a partnership, or a member or former member of any Holder that is a limited liability company, or (iv) if after such assignment or
transfer, the transferee or assignee holds at least 5% of Registrable Securities Then Outstanding, provided, however, that: (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the
name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; and (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions
of this Agreement. In the event of a transfer or assignment of Registrable Securities that does not satisfy the conditions set forth above, such securities shall no longer be deemed to constitute “Registrable Securities” for purposes of
this Agreement 
 (f) Qualified Small Business Stock. The Company covenants that so long as any Registrable Securities
are held by a Holder (in whose hands such Registrable Securities are eligible to qualify as “qualified small business stock” as defined in Section 1202(c) of the Internal Revenue Code of 1986, as amended (the “Code”)
(“Qualified Small Business Stock”)), it will (i) comply with any applicable filing or reporting requirements imposed by the Code on issuers of Qualified Small Business Stock and (ii) execute and deliver to each Holder,
from time to time, such forms, documents, schedules and other instruments as may be reasonably requested thereby to cause the Registrable Securities to qualify as Qualified Small Business Stock and in connection therewith, execute and deliver to any
such Holder, from time to time, such forms, documents, schedules and other instruments as may be reasonably requested by such Holder to cause such shares of capital stock to qualify as Qualified Small Business Stock. 

7. Restrictive Legends. Each certificate for Securities that constitute Restricted Securities shall (unless otherwise provided by
the provisions of this Agreement) be stamped or otherwise imprinted with a legend in substantially the following terms: 
 THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SAID SECURITIES MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH
ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
 The Company shall imprint such legend on certificates evidencing the Securities outstanding prior to the date hereof or issued hereafter upon the exercise of any right to acquire, whether or not
immediately exercisable, a Common Share, whether evidenced by an option, warrant convertible security or other similar instrument or agreement of the Company. The legend set forth above shall be removed from the certificates evidencing any shares
that cease to be Securities subject to this Agreement. 
 8. Remedies. Each Investor shall have all rights and remedies
reserved for such Investor pursuant to this Agreement, the Stock Purchase Agreement, all rights and remedies which such holder has been granted at any time under any other agreement or contract and all of the rights which such holder has under any
law or in equity. Any person having any rights under 

  
 14 

 
any provision of this Agreement will be entitled to enforce such rights specifically, to recover damages by reason of any breach of any provision of this Agreement and to exercise all other
rights granted by law or equity. 
 9. Miscellaneous. 

(a) Conflicting Agreements. No Investor shall enter into any agreements or arrangements of any kind with any Person with respect
to any Securities on terms inconsistent with the provisions of this Agreement (whether or not such agreements or arrangements are with other Investors or with Persons that are not parties to this Agreement), including, but not limited to, agreements
or arrangements with respect to the acquisition or disposition of securities of the Company in a manner which is inconsistent with this Agreement. 
 (b) Amendment; Waiver; or Termination. The provisions of this Agreement may only be amended, waived or terminated with the prior written consent of (i) the Company, and (ii) Investors
holding 75% of the Registrable Securities Then Outstanding. Each such amendment, waiver or termination shall be binding on each and every Investor, if such consents are obtained, regardless of whether such Investor actually approved such amendment,
waiver or termination. 
 (c) Notices. All notices, requests, demands and other communications which are required or may
be given under this Agreement shall be in writing and shall be delivered personally to the party intended to receive such notice, or sent by a national overnight delivery or courier company or by U.S. registered or certified mail, postage prepaid,
return receipt requested, and sent to: 
 If to an Investor: 

The address as set forth on Schedule A hereto. 
 If to the Company: 
 Durata Therapeutics, Inc. 

c/o New Leaf Ventures 
 7 Times Square, Suite 1603 
 New York NY 

Attn: Mr. Ron Hunt 
 Fax: (646) 519-2782 
 with a copy (which shall not constitute notice) to:

 O’Melveny & Myers LLP 

Two Embarcadero Center, 28th Floor 
 San Francisco, CA 9411 
 Attn: Peter T. Healy 

Tel: (415) 984-8833 
 Fax: (415) 984-8701 

  
 15 

 or to such other place and with such other copies as either party may designate as to itself by written
notice to the others. Any such notices shall be deemed delivered upon delivery or refusal to accept delivery as indicated in writing by the party attempting to make personal service, on the U.S. Postal Service return receipt, or by similar written
advice from the overnight delivery company; provided, however, that if any such notice shall also be sent by electronic transmission device, such as telex, telecopy, fax machine or computer to the fax
number set forth above, such notice shall be deemed delivered at the time and on the date of machine transmittal (except if sent after 5:00 p.m. recipient’s time, in which case the notice shall be deemed delivered at 9:00 a. m. on the next
business day) if the sending party receives a written send verification on its machine and sends a duplicate notice on the same day or the next business day by personal service, registered or certified U.S. mail, or overnight delivery in the manner
described above. 
 (d) Governing Law. This Agreement shall be construed in accordance with and governed by the laws of
the State of New York (without giving effect to its choice of law principles other than Section 5-1401 of the New York General Obligations Law). 
 (e) Service of Process: Consent to Jurisdiction. Each party hereto irrevocably and unconditionally: (A) agrees that any suit, action or other legal proceeding arising out of this Agreement may
be brought in the United States federal courts in or for New York, New York or, if no such court has jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in or for New York, New York; (B) consents to the
jurisdiction of any such court in any such suit, action or proceeding; and (C) waives any objection which such party may have to the laying of venue of any such suit, action or proceeding in any such court. Each party hereto irrevocably
consents to the service of any process or pleading by any method permitted under applicable law. 
 (f) Representation by
Counsel. Each party hereto represents and agrees with each other that it, he or she has been represented by, or had the opportunity to be represented by, independent counsel of its, his or her own choosing, and that it, he or she has had the
full right and opportunity to consult with its, his or her respective attorney(s), that to the extent, if any, that it, he or she desired, it, he or she availed itself of this right and opportunity, that it, he or she or its authorized officers (as
the case may be) have carefully read and fully understand this Agreement in its entirety and have had it fully explained to them by such party’s respective counsel, that each is fully aware of the contents thereof and its meaning, intent and
legal effect, and that it, he or she or its authorized officer (as the case may be) is competent to execute this Agreement and has executed this Agreement free from coercion, duress or undue influence. 

(g) Waiver. No course of dealing between the Company and the Investors (or any of them) or among the Investors, or any delay in
exercising any rights hereunder, will operate as a waiver of any rights of any party to this Agreement. The failure of any party to enforce any of the provisions of this Agreement will in no way be construed as a waiver of such provisions and will
not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms. 
 (h) Recapitalizations, Exchanges, Etc. The provisions of this Agreement shall apply, to the full extent set forth herein with respect to capital shares of the Company held by the parties hereto,
and to any and all Securities of the Company or any successor or assigns of the 

  
 16 

 
Company (whether by merger, consolidation, sale of assets, or otherwise) which may be issued in respect of, or in substitution for, such capital shares, and shall be appropriately adjusted for
any dividends, distributions, splits, reverse splits, combinations, recapitalizations and the like occurring after the date. 

(i) Severability. In the event that any one or more of the provisions contained in this Agreement or in any other instrument
referred to herein, shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, then to the maximum extent permitted by law, such invalidity, illegality or unenforceability shall not affect any other provision of this
Agreement or any other such instrument. 
 (j) Entire Agreement. This Agreement, together with all exhibits and schedules
hereto (including the other agreements referred to herein), constitutes the entire agreement among the parties pertaining to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or
written, of the parties. 
 (k) Successors and Assigns. Neither this Agreement nor any of the rights or obligations
hereunder may be assigned by any Investor. Neither this Agreement nor any of the rights or obligations hereunder may be assigned by the Company except with the consent of those parties required to effect an amendment hereto pursuant to
Section 9(b). Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. 

(1) Further Assurances. The parties hereto agree (i) to furnish upon request to each other such further information,
(ii) to execute and deliver to each other such other documents, and (iii) to do such other acts and things, all as may be reasonably requested by another party hereto for the purpose of carrying out the intent of this Agreement and the
transactions contemplated by this Agreement. 
 (m) Multiple Counterparts. This Agreement may be executed in one or more
counterparts, any of which may be executed and transmitted by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

(n) Not for Benefit of Third Parties. Except as expressly set forth herein, this Agreement is for the sole and exclusive benefit
of the parties hereto and nothing herein is intended to give or shall be construed to give any third party any rights or remedies hereunder. 
 (o) Attorneys’ Fees. If any party to this Agreement brings an action to enforce its rights under this Agreement, the prevailing party shall be entitled to recover its costs and expenses,
including without limitation reasonable attorneys’ fees, incurred in connection with such action, including any appeal of such action. 
 (p) Titles and Headings. The titles, captions or headings of the Sections herein are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement. 
 (q) No Interpretation Against Drafter. This Agreement is the product of negotiations
among the parties hereto represented by counsel and any rules of construction relating to interpretation against the drafter of an agreement shall not apply to this Agreement and are expressly waived. 

[SIGNATURE PAGES TO FOLLOW] 

  
 17 

 IN WITNESS WHEREOF, the undersigned have duly executed this Investor Rights Agreement as of
the date first written above. 
  

			
	“COMPANY”
	
	DURATA THERAPEUTICS, INC.
	
	 

	Name:	 	Dov A. Goldstein
	Title:	 	Interim Co-President
	
	  

	Name:	 	Ronald M. Hunt
	Title:	 	Interim Co-President

  

					
		 	S-1	 	Signature Page to Investor Rights Agreement

 IN WITNESS WHEREOF, the undersigned have duly executed this Investor Rights Agreement as of
the date first written above. 
  

			
	“COMPANY”
	
	DURATA THERAPEUTICS, INC.
	
	  

	Name:	 	Dov A. Goldstein
	Title:	 	Interim Co-President
	
	 

	Name:	 	Ronald M. Hunt
	Title:	 	Interim Co-President

  

					
		 	S-1	 	Signature Page to Investor Rights Agreement

 IN WITNESS WHEREOF, the undersigned have duly executed this Investor Rights Agreement as of
the date first written above. 
  

					
	“INVESTORS”	 	
		
		 	DOMAIN:
		
		 	DOMAIN PARTNERS VIII, L.P.
			
		 	By:	 	One Palmer Square Associates VIII, L.L.C.
		 	Its:	 	General Partner
			
		 	Name:	 	 

		 		 	Kathleen K. Schoemaker
		 	Its:	 	Managing Member
		
		 	DP VIII ASSOCIATES, L.P.
			
		 	By:	 	One Palmer Square Associates VIII, L.L.C.
		 	Its:	 	General Partner
			
		 	Name:	 	 

		 		 	Kathleen K. Schoemaker
		 	Its:	 	Managing Member

  

					
		 	S-2	 	Signature Page to Investor Rights Agreement

 
					
	NEW LEAF VENTURES II, L.P.
		
	By:	 	New Leaf Venture Associates II, L.P.
	Its:	 	General Partner
			
		 	By:	 	New Leaf Venture Management II, L.L.C.
		 	Its:	 	General Partner
			
		 	By:	 	 

		 		 	Ronald M. Hunt
		 		 	Managing Director

  

					
		 	S-3	 	Signature Page to Investor Rights Agreement

 
			
	CANAAN:
	
	CANAAN VIII L.P.
		
	By:	 	 

		 	Brenton K. Ahrens
	Its:	 	Member and Manager

  

					
		 	S-4	 	Signature Page to Investor Rights Agreement

 
			
	AISLING:
	
	AISLING CAPITAL III, LP
		
	By:	 	Aisling Capital Partners III, LP
	Its:	 	General Partner
		
	By:	 	Aisling Capital Partners III LLC
	Its:	 	General Partner
		
	By:	 	 

		
	Its:	 	  

  

					
		 	S-5	 	Signature Page to Investor Rights Agreement

 
					
	SOFINNOVA:
	
	SOFINNOVA VENTURE PARTNERS VII, L.P.
		
	By:	 	Sofinnova Management VII, L.L.C.
	Its:	 	General Partner
			
		 	By:	 	 

		 		 	James I. Healy,
		 		 	Managing General Partner

  

					
		 	S-6	 	Signature Page to Investor Rights Agreement

 SCHEDULE A 
 NAMES AND ADDRESSES OF INVESTORS 
  

			
	 Name
	  	 Address

		
	Domain Partners VIII, L.P.	  	 One Palmer Square
 Suite
515, Princeton, NJ 08542
 Attn: Kathleen K. Schoemaker

		
	DP VIII Associates, L.P.	  	 One Palmer Square
 Suite
515, Princeton, NJ 08542
 Attn: Kathleen K. Schoemaker

		
	New Leaf Ventures II, L.P.	  	 7 Times Square
 Suite
1603
 New York, NY 10036
 Attn: Mr. Ron
Hunt

		
	Canaan VIII, L.P.	  	 2765 Sand Hill Road
 Menlo
Park, CA 94025
 Attn: Mr. Brenton Ahrens

		
	Aisling Capital III, L.P.	  	 888 Seventh Avenue

30th Floor
 New York, NY 10106
 Attn: Dov A. Goldstein, M.D. and Mr. Lloyd Appel

		
		  	 With a copy to:
 McDermott
Will & Emery LLP
 340 Madison Avenue

New York, NY 10173
 Attn: Todd Finger,
Esq.

		
	Sofinnova Venture Partners VII, L.P.	  	 850 Oak Grove Avenue
 Menlo
Park, CA 94025
 Attn: James I. Healy, M.D., Ph.D.

  
 A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]